SciELO - Scientific Electronic Library Online

vol.27 issue2Heberprot-P: experimental background and pharmacological basesExperiences of integral care program for patients with diabetic foot in the state of Zulia, Venezuela author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Biotecnología Aplicada

On-line version ISSN 1027-2852


ALVAREZ, Eduardo; FAGET, Orestes L; ORLANDI, Neraldo  and  TORRES, Omaida F. Heberprot-P-associated metabolic control in patients with diabetic foot ulcers. Biotecnol Apl [online]. 2010, vol.27, n.2, pp.98-100. ISSN 1027-2852.

Diabetes mellitus is a unmet medical need of significant social and economical impact. Diabetic foot is a chronic and avoidable complication, and still the source of non-traumatic amputations, with metabolic imbalance, macroand micro-angiopathy, and ulceration or trauma contributing to its development. The introduction of Heberprot-P to treat diabetic foot ulcers has been a tremendous advance to reduce the amputation index and disability among patients. However, it is essential to guarantee an optimal and personalized glycemic control for achieving even more favorable results. This can be attained by implementing an intensive therapeutic strategy with multiple doses of insulin since the very first diagnose of the lesion. Due to the relevance of this topic for medical practice, here is reviewed how to establish such a therapy, and the goals for glycemic control to achieve a better quality of life when attending diabetic foot ulcer patients.

Keywords : Diabetes mellitus; diabetic foot; glycemic control; metabolic control; Heberprot-P.

        · abstract in Spanish     · text in English     · English ( pdf )